Research programme: thrombin inhibitors - Novartis
Alternative Names: Thrombin inhibitors research programme - NovartisLatest Information Update: 24 Oct 2021
At a glance
- Originator Novartis
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 26 Nov 1999 New profile
- 26 Nov 1999 Preclinical development for Thrombosis in United Kingdom (PO)